Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer

Clinical Cancer Research

Volumn 15, Issue 4, 2009, Pages 1452-1459

  Lin, Nancy U ^a   Diéras, Véronique ^b   Paul, Devchand ^c   Lossignol, Dominique ^d   Christodoulou, Christos ^e   Stemmler, Hans Joachim ^f   Roché, Henri ^g   Liu, Minetta C ^h   Greil, Richard ⁱ   Ciruelos, Eva ^j   Loibl, Sibylle ^k   Gori, Stefania ^l   Wardley, Andrew ^m   Yardley, Denise ⁿ   Brufsky, Adam ^o   Blum, Joanne L ^p   Rubin, Stephen D ^q   Dharan, Bernie ^q   Steplewski, Klaudia ^q   Zembryki, Denise ^q   Oliva, Cristina ^r   Roychowdhury, Debasish ^q   Paoletti, Paolo ^q   Winer, Eric P ^a   more..

^a DANA FARBER CANCER INSTITUTE   (United States)

^b INSTITUT CURIE   (France)

^c ROCKY MOUNTAIN CANCER CENTERS   (United States)

^d Lnstitut Jules Bordet   (Belgium)

^e METROPOLITAN HOSPITAL   (Greece)

^f LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^g INSTITUT CLAUDIUS REGAUD   (France)

^h GEORGETOWN UNIVERSITY   (United States)

ⁱ Private Medical University   (Austria)

^j HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^k UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^l SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^m CHRISTIE HOSPITAL   (United Kingdom)

ⁿ SARAH CANNON RESEARCH INSTITUTE   (United States)

^o UNIVERSITY OF PITTSBURGH   (United States)

^p Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^q GLAXOSMITHKLINE   (United States)

^r GLAXOSMITHKLINE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; TRASTUZUMAB; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; ERBB2 PROTEIN, HUMAN; FLUOROURACIL; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ARTICLE; BRAIN METASTASIS; BREAST CANCER; CANCER RADIOTHERAPY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FATIGUE; HAND FOOT SYNDROME; HEADACHE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NEUROLOGIC DISEASE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SINGLE DRUG DOSE; TREATMENT WITHDRAWAL; VOLUMETRY; VOMITING; ADULT; AGED; BRAIN TUMOR; BREAST TUMOR; DRUG ANTAGONISM; FEMALE; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; BREAST NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; PROSPECTIVE STUDIES; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, ERBB-2;

EID: 63149110733     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1080     Document Type: Article

References (19)

1. Bendell JC, Domchek SM, Burstein HJ, et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003;97:2972- 7.
2. Clayton AJ, Danson S, Jolly S, et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 2004; 91:639-43.
3. Lin NU, Winer EP. Brain metastases: the HER2 paradigm. Clin Cancer Res 2007;13:1648-55.
4. Stemmler HJ, Kahlert S, Siekiera W, Untch M, Heinrich B, Heinemann V. Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. Breast 2006;15:219-25.
5. Yau T Swanton C, Chua S, et al. Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab. Acta Oncol 2006;45:196-201.
6. Burstein HJ, Lieberman G, Slamon DJ, Winer EP, Klein P. Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. Ann Oncol 2005;16:1772-7.
7. Grossi PM, Ochiai H, Archer GE, et al. Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer. Clin Cancer Res 2003;9:5514-20.
8. Pestalozzi BC, Brignoli S. Trastuzumab in CSF. J Clin Oncol 2000;18:2349-51.
9. Pestalozzi BC, Zahrieh D, Price KN, et al. Identifying breast cancer patients at risk for central nervous system (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol 2006;17:935-44.
10. Gril B, Palmieri D, BronderJL, etal. Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J Natl Cancer Inst 2008;100:1092-103.
11. Lin NU, Carey LA, Liu MC, et al. Phase 2 trial of lapatinib for brain metastases in patients with HER2-postiive breast cancer. J Clin Oncol 2008; 26:1993-9.
12. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-43.
13. Bezjak A, Adam J, Barton R, et al. Symptom response after palliative radiotherapy for patients with brain metastases. Eur J Cancer 2002;38:487-96.
14. Kirsch DG, Ledezma CJ, Mathews CS, etal. Survival after brain metastases from breast cancer in the trastuzumab era. J Clin Oncol 2005;23:2114-6; author reply 6-7.
15. Gomez HL, Doval DC, Chavez MA, et al. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 2008;26:2999-3005.
16. Burstein HJ, Storniolo AM, Franco S, et al. A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann Oncol 2008; 19:1068-740.
17. Rivera E, Meyers C, Groves M, et al. Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. Cancer 2006;107:1348 - 54.
18. Wang ML, Yung WK, Royce ME, Schomer DF, Theriault RL. Capecitabine for 5-fluorouracil-resistant brain metastases from breast cancer. Am J Clin Oncol 2001:24:421 -4.
19. Boccardo F, Kaufman B, Baselga J, et al. Evaluation of lapatinib plus capecitabine in subjects with brain metastases from Her2+ breast cancer enrolled in the Lapatinib Expanded Access Program (LEAP) and French Authorisation Temporaire d'Utilisation [abstr 1094]. J Clin Oncol 2008;26: May 20 suppl.